-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomea Fusion reports Phase II COVALENT-111 data showing 1% HbA1c reduction at Week 52 with icovamenib in type 2 diabetes patients

Reuters·03/14/2026 08:30:16

Please log in to view news